1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Norway Pharmaceuticals and Healthcare Report Q3 2016

Norway Pharmaceuticals and Healthcare Report Q3 2016

  • July 2016
  • -
  • Business Monitor International
  • -
  • 62 pages

Includes 3 FREE quarterly updates

BMI View: Norway's life sciences and biomedical research base will continue to develop at a sustainedpace, which will enhance investment opportunities over the medium to long term. Meanwhile, Norway'songoing expansionary fiscal policy, as well as market growth fundamentals, will underpin a sustainedgrowth trajectory in its pharmaceutical and healthcare market over a multi-year horizon.

Headline Expenditure ProjectionsPharmaceuticals: NOK23.40bn (USD2.78bn) in 2015 to NOK23.67bn (USD2.72bn) in 2016; +1.2% inlocal currency terms and -1.9% in US dollar terms. Forecast revised upwards from last quarter.Healthcare: NOK316.68bn (USD37.56bn) in 2015 to NOK327.79bn (USD37.71bn) in 2016; +3.5% inlocal currency terms and +0.4% in US dollar terms. Forecast revised upwards from last quarter.

Table Of Contents

Norway Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Norway 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Norway 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Norway 2012-2020) 22
Pharmaceutical Trade Forecast 23
Table: Pharmaceutical Trade Data And Forecasts (Norway 2014-2020) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (Norway 2014-2020) 25
Industry Risk/Reward Index 26
Western Europe Risk/Reward Index 26
Norway Risk/Reward Index 31
Rewards 31
Risks 31
Regulatory Review 33
Pricing Regime 35
Reimbursement Regime 36
Market Overview 39
Healthcare Sector 40
Table: Healthcare Resources (Norway 2010-2015) 41
Table: Healthcare Personnel (Norway 2010-2015) 41
Table: Healthcare Activity (Norway 2010-2015) 42
Research And Development 42
Clinical Trials 43
Epidemiology 44
Competitive Landscape 46
Table: The Top 25 Pharmaceutical Companies In Norway 47
Table: Multinational Market Activity 48
Demographic Forecast 51
Table: Population Headline Indicators (Norway 1990-2025) 52
Table: Key Population Ratios (Norway 1990-2025) 52
Table: Urban/Rural Population and Life Expectancy (Norway 1990-2025) 53
Table: Population By Age Group (Norway 1990-2025) 53
Table: Population By Age Group % (Norway 1990-2025) 54
Glossary 56
Methodology 58
Pharmaceutical Expenditure Forecast Model 58
Healthcare Expenditure Forecast Model 58
Notes On Methodology 59
Risk/Reward Index Methodology 60
Index Overview 61
Table: Pharmaceutical Risk/Reward Index Indicators 61
Indicator Weightings 62

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.